Who Paid My Doc
Rizwan Bukhari
Mesquite, TX Medical Doctor
NPI 1225076227 CMS profile 282576
3865 Childress Ave, Suite C, Mesquite, TX 75150
General payments
$44,747
Research payments
$0
Ownership & investment interest
$299,925
Through program year 2025, Rizwan Bukhari of Mesquite, TX is reported in the CMS Open Payments database as having received $44,747 across 158 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $299,925 across 3 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30,138 | 32 | |
| 2024 | General | $1,177 | 33 | |
| 2023 | General | $11,369 | 13 | |
| 2022 | General | $522 | 20 | |
| 2021 | General | $420 | 21 | |
| 2020 | General | $850 | 21 | |
| 2019 | General | $271 | 18 | |
| 2025 | Ownership | $99,975 | 1 | |
| 2024 | Ownership | $99,975 | 1 | |
| 2023 | Ownership | $99,975 | 1 |
Beside peers
- Rizwan Bukhari
- Texas median
- Middle half of Texas
- National median
In program year 2025, general payments to Rizwan Bukhari were reported at $30,138. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.
Show as a table
| Year | Rizwan Bukhari | Texas median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $271 | $191 | $56–$744 | $163 |
| 2020 | $850 | $125 | $38–$452 | $114 |
| 2021 | $420 | $150 | $43–$543 | $132 |
| 2022 | $522 | $169 | $50–$606 | $149 |
| 2023 | $11,369 | $183 | $53–$639 | $160 |
| 2024 | $1,177 | $188 | $55–$666 | $164 |
| 2025 | $30,138 | $188 | $55–$669 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
112
Drug cost
$18,985
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 15 | $18,206 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 86 | $674 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 11 | $105 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 74 billing codesPaid by Medicare
$509,215
Medicare patients
172
Services billed
1,256
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 61% | |
| Arthritis | 52% | |
| Ischemic heart disease | 47% | |
| Chronic kidney disease | 47% | |
| Heart failure | 35% | |
| COPD | 34% | |
| Depression | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
158 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.